Image credit: © Sabrina | stock.adobe.com
Women are missing from medicines development: EMA’s roadmap for change
10 priorities proposed to drive change in medicines for women’s health
By the end of 2026, EMA will develop a regulatory roadmap to help drive decisive change on how women’s health is considered across medicines development and regulation. This follows a multistakeholder workshop held on 28 and 29 September in Amsterdam where participants converged on a series of priority actions.
While women represent half of the world’s population, persistent gaps in research, evidence generation, and medicines development mean that many of their specific health needs remain insufficiently understood and addressed, contributing to poorer health outcomes and unmet medical needs.
The multistakeholder workshop, broadcast live, brought together over 100 leading voices on women’s health at EU and international level, from regulators to patients, healthcare professionals, non-governmental organisations (NGOs), industry and academia.
Over two days, the participants prioritised 10 proposed actions. These cover areas where EMA could lead, collaborate, or influence. The broad consensus among the diverse participants on the priority actions highlighted clear opportunities for change through greater global alignment.
The priority actions will feed into a roadmap on medicines for women’s health, which will include concrete deliverables with planned short-, medium- and long-term timelines. The roadmap, together with the workshop report, are planned for publication by the end of 2026.
Excerpt from the official page. The original is authoritative.